(Total Views: 407)
Posted On: 03/10/2021 3:20:40 PM
Post# of 154082
“Do you see the dichotomy in those two statements?”
Yes, that’s the point. The FDA is not going to approve the combo BLA based on a 47 patient trial SO when efficacy at a higher dose was noted, the FDA recommended combing data from both trials for a more robust clinical section. Pretty simple understand unless NP is explaining it.
Yes, that’s the point. The FDA is not going to approve the combo BLA based on a 47 patient trial SO when efficacy at a higher dose was noted, the FDA recommended combing data from both trials for a more robust clinical section. Pretty simple understand unless NP is explaining it.
(1)
(0)
